Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
about
Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.Etanercept-associated transient bone marrow aplasia: a review of the literature and pathogenetic mechanisms.Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodiesCardiovascular co-morbidity in patients with rheumatic diseases.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditionsUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Decreased serum cell-free DNA levels in rheumatoid arthritis.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Infliximab for the treatment of ankylosing spondylitis.Glomerulonephritis, Th1 and Th2: what's new?Toxicity of infliximab in the course of treatment of Crohn's disease.Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis CMonitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesAntigen-specific immunotherapy for autoimmune diseases.Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionSulfatide attenuates experimental Staphylococcus aureus sepsis through a CD1d-dependent pathway.Perioperative management of medications used in the treatment of rheumatoid arthritis.TNFR1 signaling kinetics: spatiotemporal control of three phases of IKK activation by posttranslational modification.Long-term use of adalimumab in the treatment of rheumatic diseases.Etanercept: an introduction.Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.Light on the horizont: biologicals in Behçet uveitis.Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder?Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.The combination of a tumor necrosis factor inhibitor and antibiotic alleviates staphylococcal arthritis and sepsis in mice.Effects of a novel peptide derived from human thrombomodulin on endotoxin-induced uveitis in vitro and in vivo.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].CTLA4 Immunoglobulin but Not Anti-Tumor Necrosis Factor Therapy Promotes Staphylococcal Septic Arthritis in Mice.Abatacept in the treatment of rheumatoid arthritis.Visual recovery following Mycobacterium chelonae endophthalmitis.The biologics era: a revolution in arthritis management.The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis.Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment.Infliximab for rheumatoid arthritis.Emergence of Legionella pneumophila Pneumonia in Patients Receiving Tumor Necrosis Factor- Antagonists
P2860
Q24816844-5B351700-8E2A-4FF5-984E-54B996FCA508Q30240180-A1FF69B2-341C-48EA-ADCE-66C7AF84CBD4Q30647378-BFA62CCD-3000-4AFA-A36D-E111699BC97CQ33804799-3DB57D38-A182-4FD2-8020-3F9C4A00F28BQ33934927-3C150B11-BB61-4779-B188-3A8B0C360C85Q35557796-526DFA17-25DE-48EA-BE68-683454D3A837Q35579517-64142E20-4AE8-4105-8220-CE8CE691CAFDQ35637995-F7932006-8D6F-4585-8C00-A49EC7DFF14CQ35638252-7EC645F4-92F6-4102-9DDC-3B7EB7ED6987Q35952500-77C1ECAF-0D5D-4827-A8C2-38E3CDBCC706Q36171750-FD08C55C-1433-47E7-A987-A45C988507EDQ36210882-D5439C33-73B6-46E4-909A-892BA28B8B11Q36289545-AD88C27A-698A-4BA1-8BD7-AB2EB22CFC95Q36349717-0EA8CAD5-6E8B-44D7-9DFC-AE54A1FADF34Q36522235-F51C4C58-2795-4BE0-8FE4-D7B2D1985282Q36724093-238FEA56-2F92-42E3-AB71-11DAE858887EQ36739772-B00FE3C6-F6DE-42F6-ADD9-A7CF4D172479Q36778450-BCBA51C8-DEEB-409B-8345-F537A34BF625Q36804654-97BE7CB1-678D-45E3-9A54-BEE97B749849Q37254250-F6BCF92D-6A5F-49B3-9C2C-3D97C910F220Q37299479-421409DE-8C08-4093-99D1-F8E870961B63Q37358124-767ADAB9-6FE8-4FF9-88B9-9E185465D431Q37754607-1CB90802-16FB-47D4-BCCB-B35149637F46Q37915351-C392DCC5-9400-4783-94EF-058E4FD213B6Q38004097-9F627702-CC5C-49DC-A5BD-0C0CE3250ABFQ38171360-E65B1496-722C-4CFF-B18F-3B633039E72DQ38451783-D9DDA607-FED5-4758-8357-BD23DA48D54FQ38615340-D22CCD01-E131-4C32-93BB-9645F542E362Q39119839-5800AB9B-9E0A-44B8-8391-646186A02507Q39262917-0F8FB9C5-4D1F-456F-92AD-E621082C0F61Q39457809-C6A88C88-6783-4479-92E7-671F5EFDE082Q41176187-35D0D283-7B33-4D1C-B116-B8E909AA1B37Q41358884-3A4AA056-8546-4E91-BE63-E3B9ADAB6903Q41905727-B146AE8E-8CD9-434D-B03A-AEC74034F388Q44434193-DA51CD14-4381-4BB9-B8D8-9AE5F13EDF60Q44752619-9704DFED-DDE0-4F14-9977-B8C5D294A32AQ45861457-A0157E29-D8F0-4A00-83AC-7C6347C70DB9Q46812628-BFB2AC8D-CED0-42ED-B5CC-956557FB840CQ52856626-5B3BE658-763F-452B-A6B0-CB9E3F6CD45EQ57779961-5FF6A563-F163-4C05-94AF-3A4C9B30DDA0
P2860
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
@ast
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
@en
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
@nl
type
label
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
@ast
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
@en
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
@nl
prefLabel
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
@ast
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
@en
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
@nl
P2093
P2860
P356
P1476
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
@en
P2093
P2860
P304
P356
10.1136/ARD.2004.024737
P407
P577
2004-07-08T00:00:00Z